EL-32 / PMGC Holdings, MOA Life Plus, NorthStrive Biosciences - LARVOL DELTA

NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets (Yahoo Finance) - "Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss; Filed applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support....The applications have been assigned U.S. Patent Application Nos. 19/709,895 (EL-22) and 19/709,950 (EL-32)....These human-use filings build on and differentiate the portfolio from NorthStrive's previously announced animal-focused filings, seeking to extend the EL-22 and EL-32 inventions to human patients and the growing GLP-1 and obesity-related weight loss market."

Patent • Obesity

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences (GlobeNewswire) - "This transfer initiates a manufacturing optimization program designed to increase production yield and establish a cost-efficient, scalable process in support of future clinical and commercial development....The parties’ collaboration reflects a dual-track development strategy: NorthStrive Biosciences retains all rights to human therapeutic applications of EL-32, while Modulant Biosciences holds an exclusive license to develop and commercialize EL-32-derived products for non-human animal health applications. This parallel approach is intended to maximize the commercial potential of the EL-32 platform across both markets while leveraging shared manufacturing and process development insights."

Licensing / partnership • Obesity

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments (GlobeNewswire) - "The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties’ research and development and regulatory expectations...Northstrive Biosciences believes the Amendment reinforces the company’s commitment to disciplined development planning and the continued progression of its human health portfolio."

Licensing / partnership • Obesity

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health (GlobeNewswire) - "These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists. The Company filed the following four patents today: (i) EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals (Patent Application No. 19/191,246); (ii) EL-32 in Obesity as Monotherapy and Combination with GLP-1: Updated patent filings for Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatments (Patent Application No. 19/191,209), and Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments utilizing GLP-1 receptor agonists (Patent Application No. 19/191,226); (iii) EL-32 in Animals: Animal Feed Additive to Encourage Muscle Growth (Patent Application No. 19/191,258)."

Patent • Obesity

EL-32: Engaged CRO for Preclinical Study (GlobeNewswire) - "Northstrive has entered into a research agreement with a leading preclinical contract research organization (CRO) specializing in metabolic disorders. The research agreement will support a planned study to evaluate EL-32, an engineered probiotic expressing dual myostatin and activin-A inhibitors, both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide. The focus of the study will be on glycemic control and body composition in diet-induced obese (DIO) mice...Northstrive will present its novel obesity drug candidates at the exclusive UCLA Obesity Symposium...The presentation....is scheduled for Friday, February 7, 2025."

Commercial • Pipeline update • Obesity